Teva CEO Steps Down - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Teva CEO Steps Down


Teva Pharmaceutical Industries reported on Oct. 30, 2013 that Jeremy Levin, president and CEO, will step down immediately. Eyal Desheh, Teva's executive vice-pesident and chief financial officer, will fill the role of president and CEO on an interim basis. The company's board of directors has formed a committee that will begin to search for a permanent successor.

The change in leadership at Teva follows a recently announced restructuring program. In October 2013, Teva announced plants to accelerate its restructuring program, which was introduced in December 2012 and included actions to divest noncore assets, increase organization effectiveness, improve manufacturing efficiency, and reduce excess capacity. Teva plans to reduce its global workforce by approximately 10% (approximately 5000 employees) and will complete the majority of the reduction by the end of 2014.

Teva recently reported its third-quarter results. Revenues for the three months ended September 30, 2013 were $5.1 billion, an increase of 2% compared to the third quarter of 2012. In local currency terms, revenues also went up 2%. The increase was primarily attributable to higher sales of generic medicines in the United States, higher revenues from its global specialty and over-the-counter medicines. This increase was partially offset by a decrease in global API sales to third parties.

See related story, "Teva Announces Further Restructuring."

Source: Teva Pharmaceutical Industries (Third-Quarter Results); Teva Pharmaceutical Industries (Executive Change)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here